Web Results

www.sec.gov/litigation/complaints/2012/comp-pr2012-237.pdf

Nov 20, 2012 ... Elan and Wyeth to present the final clinical trial results at a July 29, 2008 medical conference, which was to coincide with the after-market hours public announcement of the trial results by the two companies (the "July 29 Announcement"). 3. Martoma met Gilman through paid consultations that took place ...

www.sec.gov/news/press-release/2012-2012-237htm

Nov 20, 2012 ... The SEC alleges that Mathew Martoma illegally obtained confidential details about the clinical trial from Dr. Sidney Gilman, who served as chairman of the safety monitoring committee overseeing the trial. Dr. Gilman was selected by Elan Corporation and Wyeth to present the final drug trial results to the ...

www.ca6.uscourts.gov/opinions.pdf/11a0271p-06.pdf

Sep 22, 2011 ... Before: DAUGHTREY, GILMAN, and SUTTON, Circuit Judges. 1 ... Smith, et al. v. Wyeth, Inc., et al. Page 3. 1. Although Smith and Wilson claim to have consumed only generic metoclopramide, plaintiff. Morris does assert that he consumed some Reglan manufactured by Wyeth (but not Schwarz), a fact that.

www.crintrinsicfairfund.com

On November 20, 2012, the SEC brought suit against CR Intrinsic Investors, LLC (“CR Intrinsic”) and Matthew Martoma and Dr. Sidney Gilman. ... losses in July 2008 by trading ahead of a negative public announcement involving the clinical trial results for an Alzheimer's drug being jointly developed by Elan and Wyeth.

www.newyorker.com/magazine/2014/10/13/empire-edge

Oct 13, 2014 ... By the time Gilman made his presentation, however, S.A.C. Capital no longer owned any stock in Elan or Wyeth. In the eight days preceding the conference, Cohen had liquidated his seven-hundred-million-dollar position in the two companies, and had then proceeded to “short” the stocks—to bet against ...

www.lexology.com/library/detail.aspx?g=67e0fa55-ab2c-4938-907a-96beae53d4fa

Aug 29, 2017 ... Predictably, Elan's and Wyeth's share prices increased following this announcement. A few weeks before the conference, Dr.Gilman learned that the trial results were actually worse than expected, and he immediately informed Martoma about the bad news, providing him with extensive data about the ...

www.linkedin.com/in/tom-gilman-a5b519

View Tom Gilman's professional profile on LinkedIn. LinkedIn is the world's largest business network, helping professionals like Tom Gilman discover inside connections to recommended job candidates, industry experts, and business partners.

www.linkedin.com/in/steve-gilman-775522a

View Steve Gilman's profile on LinkedIn, the world's largest professional community. Steve has 13 jobs listed on their profile. See the complete profile on LinkedIn and discover Steve's connections and jobs at similar companies.

www.bloomberg.com/research/stocks/people/person.asp?personId=9363518&capId=112206719&previousCapId=&previousTitle=

Dr. Steven C. Gilman, also known as Steve, Ph.D., has been the Chief Executive Officer and President of ContraFect Corporation since July 21, 2016 and as its Executive Chairman since May 20, 2015. Dr. Gilman is on Leave of Absence. Dr. Gilman served as an Interim Chief Executive Officer of ContraFec.